Tarsus

Tarsus Pharmaceuticals applies proven science and new technology to revolutionize treatment for patients, starting with eye care. It is advancing its pipeline to address several diseases with high unmet need across a range of therapeutic categories, including eye care, dermatology, and infectious disease prevention. The company is studying several investigational medicines in clinical trials. Its lead product candidate, TP-03, is a novel therapeutic being studied in a second pivotal trial for the treatment of Demodex blepharitis. In addition, Tarsus is developing TP-05, an oral, non-vaccine therapeutic for the prevention of Lyme disease, currently studied in a Phase 1b clinical trial.